Supernus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	73.87	1.32	60.71	53.42
Depreciation & Amortization	80.41	84.86	85.54	32.6
Other Amortization	-	0.53	2.11	17.5
Asset Writedown & Restructuring Costs	-	20.19	-	15
Loss (Gain) From Sale of Investments	1.81	-0.12	3.22	0.07
Loss (Gain) on Equity Investments	-	-	-12.89	-
Stock-Based Compensation	27.76	26.76	17.57	17.91
Other Operating Activities	-9.85	-13.31	-15.2	-12.94
Change in Accounts Receivable	2.08	18.77	-16.37	3.87
Change in Inventory	15.81	6.11	-17.86	-14.58
Change in Accounts Payable	-15.02	-36.29	-19.16	18.18
Change in Other Net Operating Assets	-4.92	2.28	29.14	-3.9
Operating Cash Flow	171.95	111.09	116.83	127.13
Operating Cash Flow Growth	54.79%	-4.91%	-8.10%	-8.14%
Capital Expenditures	-0.73	-0.55	-0.41	-2.05
Cash Acquisitions	-	-	-	-311.69
Investment in Securities	-189.14	269.28	-216.25	231.82
Investing Cash Flow	-189.87	268.73	-216.66	-81.91
Short-Term Debt Issued	-	93	-	-
Long-Term Debt Issued	-	-	-	0.8
Total Debt Issued	-	93	-	0.8
Short-Term Debt Repaid	-	-93	-	-
Long-Term Debt Repaid	-	-402.5	-	-138.32
Total Debt Repaid	-	-495.5	-	-138.32
Net Debt Issued (Repaid)	-	-402.5	-	-137.52
Issuance of Common Stock	14.91	6.61	12.42	7.1
Repurchase of Common Stock	-2.72	-1.99	-	-
Other Financing Activities	-	-	-22.9	-
Financing Cash Flow	12.19	-397.88	-10.48	-130.42
Net Cash Flow	-5.72	-18.07	-110.31	-85.21
Free Cash Flow	171.23	110.53	116.41	125.08
Free Cash Flow Growth	54.91%	-5.05%	-6.93%	-7.15%
Free Cash Flow Margin	25.87%	18.19%	17.45%	21.57%
Free Cash Flow Per Share	3.06	1.99	1.89	2.30
Cash Interest Paid	-	1.95	2.52	2.52
Cash Income Tax Paid	53.25	36.6	16.2	25.19
Levered Free Cash Flow	155.22	161.71	89.54	116.37
Unlevered Free Cash Flow	155.22	162.69	91.84	113.51
Change in Working Capital	-2.05	-9.14	-24.24	3.57

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q